Adding palbociclib, a CDK4/6 inhibitor, to MLN0128, could even potentiate its anti-tumor effects for iCCA (Song et al., 2019) making dual kinase inhibition of mTORC1/2 a promising treatment strategy for CCA. This evidence concerns the gene CDK4 and neoplasm.